1h Free Analyst Time
The bladder cancer market is forecasted to grow by USD 2.44 billion during 2023-2028, accelerating at a CAGR of 11.4% during the forecast period. The report on the bladder cancer market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising incidence of bladder cancer, increasing geriatric population, and bladder cancer awareness campaigns.
The bladder cancer market is segmented as below:
By Disease Type
- Transitional cell carcinoma
- Others
By Drug Class
- Immunotherapy drugs
- Chemotherapy drugs
- Target therapy drugs
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the bladder cancer market covers the following areas:
- Bladder Cancer Market sizing
- Bladder Cancer Market forecast
- Bladder Cancer Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Disease Type
9 Market Segmentation by Drug Class
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global bladder cancer market: Adaptimmune Therapeutics plc, Amneal Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Bavarian Nordic AS, Bristol Myers Squibb Co., Eli Lilly and Co., Endo International Plc, Ferring BV, Incyte Corp., Johnson and Johnson Inc., MEDYRA PHARMACEUTICAL, Merck and Co. Inc., Merck KGaA, Nanostics, Pfizer Inc., and UroGen Pharma Ltd.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is approval of new drugs."
According to the report, one of the major drivers for this market is the rising incidence of bladder cancer.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adaptimmune Therapeutics plc
- Amneal Pharmaceuticals Inc.
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bavarian Nordic AS
- Bristol Myers Squibb Co.
- Eli Lilly and Co.
- Endo International Plc
- Ferring BV
- Incyte Corp.
- Johnson and Johnson Inc.
- MEDYRA PHARMACEUTICAL
- Merck and Co. Inc.
- Merck KGaA
- Nanostics
- Pfizer Inc.
- UroGen Pharma Ltd
